Yahoo Finance

First Clinical Study of SeptAlign™ Implant Demonstrates Safety and Efficacy in Treating Nasal Septal Deviation While Preserving Cartilage

SOUTH SAN FRANCISCO, Calif., June 12, 2025--(BUSINESS WIRE)--Spirair, Inc., an early-stage company developing minimally invasive solutions to help ENTs improve patient care, today announced the ...
Business Wire

Spirair Receives FDA Clearance for SeptAlign, the First and Only Minimally Invasive Therapy for Mechanical Correction of Nasal Septal Deviation

New therapy provides a minimally invasive option for ENTs to straighten minor deviations in septal cartilage and help address nasal airway obstruction SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...
BioWorld

It’s Spirair by a nose as Septalign gains FDA clearance

Spirair Inc. won the race for the first U.S. FDA 510(k) clearance for a minimally invasive therapy for nasal septal deviation (NSD), the company said. The Septalign system features a bioabsorbable ...
Pharmabiz

Spirair receives US FDA clearance for TurbAlign, a new bioabsorbable implant that helps keep nasal passages open after sinus surgery

Spirair, Inc., an early-stage medical device company developing minimally invasive solutions to help ENTs improve patient care, announced that the US Food and Drug Administration (FDA) has granted 510 ...